Therefore, strategies to increase TIMP3 activity specifically in hepatocytes may be explored as a valuable therapeutic approach to attenuate NAFLD development and liver tumor progression. This evidence concerns the gene TIMP3 and metabolic dysfunction-associated steatotic liver disease.